Table 1.
Patient baseline characteristics pre and post BPA
| Pre BPA (n = 38) | Post BPA (n = 38) | P-value | |
|---|---|---|---|
| Demographic characteristics | |||
| Age (years) | 65.0 ± 14.6 | ||
| Female gender, n (%) | 23 (61) | ||
| Length (cm) | 173.6 ± 9.2 | ||
| Weight (kg) | 83.6 ± 17.8 | ||
| BMI (kg/m2) | 27.9 ± 6.2 | ||
| BSA (m2) | 2.0 ± 0.2 | ||
| Medical history, n (%) | |||
| Smokers (ever) | 11 (29) | ||
| COPD | 6 (16) | ||
| Hypertension | 11 (29) | ||
| Diabetes | 3 (8) | ||
| Coronary artery disease | 2 (5) | ||
| Thyroid dysfunction | 3 (8) | ||
| Coagulation disorder | 4 (11) | ||
| Venous thromboembolism | 33 (87) | ||
| Pharmacologic therapy,n (%) | |||
| VKA/NOAC | 15 (39)/23 (61) | ||
| Diuretics | 14 (37) | ||
| No PH medication | 7 (18) | 5 (13) | 0.500 |
| sGC stimulator | 8 (21) | 10 (26) | 0.500 |
| PDE5‑i | 3 (9) | 4 (11) | 1.000 |
| ERA | 5 (13) | 8 (21) | 0.250 |
| sGC stimulator + ERA | 7 (18) | 6 (16) | 1.000 |
| PDE5-i + ERA | 8 (21) | 5 (13) | 0.250 |
| Clinical characteristics | |||
| WHO FC I/II/III/IV (%) | 0/63/34/3 | 39/50/11/0 | 0.014 |
| NT-proBNP (pg/ml), median (IQR), n = 36 | 195 (96–1812) | 154 (71–387) | 0.078 |
| Log NT-proBNP (pg/ml), n = 36 | 2.5 ± 0.8 | 2.2 ± 0.6 | 0.008 |
| 6MWD (m), n = 31 | 374 ± 124 | 422 ± 125 | 0.007 |
| Right-sided heart catheterisation | |||
| Heart rate (bpm), n = 31 | 72.3 ± 11.6 | 71.6 ± 11.8 | 0.630 |
| CO (l/min), n = 36 | 5.7 ± 2.3 | 6.0 ± 1.6 | 0.510 |
| CI (l/min/m2), n = 36 | 2.9 ± 1.1 | 3.0 ± 0.8 | 0.479 |
| SVi (ml/m2), n = 31 | 37.5 ± 10.9 | 43.2 ± 10.2 | 0.009 |
| Mean RAP (mm Hg), n = 33 | 8.9 ± 3.5 | 6.9 ± 3.0 | 0.006 |
| Systolic PAP (mm Hg) | 63.6 ± 19.8 | 50.6 ± 15.0 | 0.0001 |
| Diastolic PAP (mm Hg) | 24.1 ± 6.1 | 18.4 ± 4.2 | 0.0001 |
| Mean PAP (mm Hg) | 39.5 ± 11.6 | 30.6 ± 8.2 | 0.0001 |
| PAWP (mm Hg) | 11.5 ± 2.7 | 12.1 ± 3.6 | 0.340 |
| PVR (WU), n = 36 | 6.1 ± 4.7 | 3.3 ± 2.0 | 0.0001 |
Data are presented as mean ± standard deviation or median (interquartile range)
BPA balloon pulmonary angioplasty, SD standard deviation, BMI body mass index, BSA body surface area, COPD chronic obstructive pulmonary disease, VKA vitamin K antagonist, NOAC novel oral anticoagulants, PH pulmonary hypertension, sGC soluble guanylyl cyclase, PDE5‑i phosphodiesterase type 5 inhibitor, ERA endothelin receptor antagonist, WHO FC World Health Organisation functional class, NT-proBNP N-terminal pro-brain natriuretic peptide, IQR interquartile range, 6MWD 6-minute walking distance, CO cardiac output, CI cardiac index, SVi stroke volume index, RAP right arterial pressure, PAP pulmonary artery pressure, PAWP pulmonary artery wedge pressure, PVR pulmonary vascular resistance